Self-Regulated Release of Active Pharmaceutical Ingredient for Niche Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts the original self-regulated release technology for specialized markets, such as disaster relief, high-security environments, extreme weather conditions, remote medical assistance, and areas with limited medical resources.
Background and Problem Solved
The original patent addressed the need for abuse deterrent pharmaceutical compositions. However, these compositions may not be suitable for specific, narrow markets or unique operational environments. This inventive concept solves the problem by adapting the self-regulated release technology to cater to these niche applications.
Detailed Description of the Inventive Concept
The inventive concept comprises specialized variations of the original pharmaceutical composition, including a portable container with a water purification system for disaster relief, a secure, tamper-evident monitoring system for high-security environments, a moisture-resistant coating with a desiccant for extreme weather conditions, a telemedicine platform for remote medical assistance, and educational materials for areas with limited medical resources. These variations ensure the safe and effective administration of the pharmaceutical composition in these unique environments.
Novelty and Inventive Step
The new claims introduce novel and non-obvious adaptations of the original self-regulated release technology, including the integration of water purification systems, secure monitoring systems, moisture-resistant coatings, telemedicine platforms, and educational materials. These adaptations provide a new level of safety and efficacy in niche applications, distinguishing the inventive concept from the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include using different types of containers, monitoring systems, or coatings, or integrating additional features such as GPS tracking or biometric authentication. Variations could also include adapting the pharmaceutical composition for different types of medications or diseases.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in various industries, including disaster relief, healthcare, pharmaceuticals, and medical technology. The target markets include governments, NGOs, hospitals, clinics, and pharmaceutical companies operating in niche environments.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K47/02 |
| A | A61 | A61K9/2009 |
| A | A61 | A61K9/2027 |
| A | A61 | A61K9/2077 |
| A | A61 | A61K31/5517 |
| A | A61 | A61K47/32 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical formulation and drug delivery systems, with specialized expertise in abuse-deterrent medication design, controlled release technologies, and pharmaceutical composition modification
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or formulation engineer with advanced degree, experience in drug delivery system design, knowledge of controlled release mechanisms, and understanding of pharmaceutical packaging and administration technologies
Obviousness Rationale
A PHOSITA would recognize that the source patent's core technology of self-regulated pharmaceutical release provides a foundational framework for adapting the composition to specialized environments. The PTD's variations represent predictable extensions of the original abuse-deterrent technology, applying known pharmaceutical engineering principles to solve contextual administration challenges. The modifications demonstrate standard problem-solving approaches within pharmaceutical design, utilizing well-established techniques of packaging, monitoring, and environmental protection.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,629 |
|---|---|
| Title | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
| Assignee(s) | Acurx Pharmaceuticals, Inc. |